Abbott’s Freestyle Libre 3 now compatible with mylife Loop AID system
2022-12-22
The AID system incorporates technology from CamDiab's algorithm that automatically adjusts insulin dosage on mylife YpsoPump, an insulin pump from Ypsomed, based on FreeStyle Libre 3 sensor data
Abbott Freestyle Libre 3 Sensor. (Credit: Abbott)
Abbott announced that its FreeStyle Libre 3 sensor can be now used with the mylife Loop solution from Swiss infusion systems specialist Ypsomed and digital health firm CamDiab.
The integration will create a smart, automated solution that delivers insulin based on real-time glucose data.
It combines CamDiab’s CamAPS FX mobile app and Ypsomed’s mylife YpsoPump with accurate, real-time data from Abbott’s FreeStyle Libre 3 sensor.
The company is offering the automated insulin delivery system (AID) solution currently in Germany, with plans to expand to additional European countries starting in 2023.
In addition to partnership with Ypsomed and CamDiab, it is also working with other insulin delivery systems interoperability with its FreeStyle Libre platform, said Abbott.
Abbott diabetes care business senior vice president Jared Watkin said: “Our FreeStyle Libre portfolio is already helping to improve the lives of 4.5 million people around the world who are living with diabetes.
“We’re partnering with diabetes and digital health technology leaders like Ypsomed and CamDiab to deliver new innovative solutions that make diabetes care as easy as possible, so people can spend less time worrying about their diabetes and more time living.”
According to JDRF’s Type 1 Diabetes Index, an average person living with Type 1 diabetes in Germany loses 18.5 healthy years, if their diabetes is not properly managed.
Effective glucose monitoring and automated insulin delivery devices could help people with diabetes restore around five healthy years.
Abbott said that its integrated solution will continuously monitor a person’s glucose levels, and automatically adjusts and delivers the right amount of insulin at the right time.
Its AID solution will eliminate the issues related to insulin dosing and helps people with diabetes reach better treatment targets, said the company.
HealthPartners Institute international diabetes centre executive director Rich Bergenstal said: “As healthcare providers, one of the biggest challenges of insulin therapy is when glucose levels get dangerously low.
“Technological innovations, like automated insulin delivery systems, can ease some of that uncertainty by continuously monitoring a person’s glucose levels and delivering the right insulin dosage, which can ultimately improve time in range. And better glucose control reduces diabetes complications.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。